VIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in Nurix Therapeutics, Inc. $NRIX

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,400 shares of the company’s stock, valued at approximately $141,000.

Other institutional investors have also recently bought and sold shares of the company. E Fund Management Co. Ltd. acquired a new position in Nurix Therapeutics during the first quarter worth about $122,000. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in Nurix Therapeutics during the first quarter worth about $169,000. KLP Kapitalforvaltning AS raised its stake in Nurix Therapeutics by 38.7% during the second quarter. KLP Kapitalforvaltning AS now owns 15,400 shares of the company’s stock worth $175,000 after acquiring an additional 4,300 shares in the last quarter. Hsbc Holdings PLC raised its stake in Nurix Therapeutics by 32.9% during the first quarter. Hsbc Holdings PLC now owns 16,095 shares of the company’s stock worth $189,000 after acquiring an additional 3,988 shares in the last quarter. Finally, Arizona State Retirement System raised its position in Nurix Therapeutics by 8.7% in the first quarter. Arizona State Retirement System now owns 17,253 shares of the company’s stock valued at $205,000 after purchasing an additional 1,385 shares during the last quarter.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 5,402 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $11.03, for a total value of $59,584.06. Following the sale, the chief financial officer directly owned 35,512 shares in the company, valued at $391,697.36. This represents a 13.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Gwenn Hansen sold 4,308 shares of the company’s stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total value of $51,739.08. Following the completion of the sale, the insider owned 69,023 shares in the company, valued at $828,966.23. The trade was a 5.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,014 shares of company stock worth $163,014 over the last quarter. 7.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

NRIX has been the subject of several research reports. Stifel Nicolaus set a $33.00 target price on Nurix Therapeutics in a research report on Friday, October 10th. Oppenheimer lowered their price objective on Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating for the company in a research note on Friday, October 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nurix Therapeutics in a research note on Saturday. UBS Group lowered their price objective on Nurix Therapeutics from $30.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday, July 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Nurix Therapeutics in a research note on Monday, October 20th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $27.07.

Nurix Therapeutics Price Performance

Shares of NRIX stock opened at $11.09 on Monday. The business’s 50 day simple moving average is $9.49 and its 200 day simple moving average is $10.54. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56. The stock has a market capitalization of $852.60 million, a PE ratio of -3.73 and a beta of 2.33.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Thursday, October 9th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.19). Nurix Therapeutics had a negative net margin of 292.50% and a negative return on equity of 53.57%. The company had revenue of $7.89 million during the quarter, compared to the consensus estimate of $16.06 million. As a group, research analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.